Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. James Porter, Ph.D., the company's Chief Executive Officer, will deliver a presentation on Tuesday, January 14, 2025, at 9:00 a.m. PT in San Francisco. The presentation will be accessible via live webcast through the Investors section of Nuvalent's website and will remain available for 30 days afterward.

News Market Reaction – NUVL

+1.43%

1 alert

+1.43% News Effect

On the day this news was published, NUVL gained 1.43%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

12/19/2024 - 06:30 AM

CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:00 a.m. PT in San Francisco.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302335786.html

SOURCE Nuvalent, Inc.

FAQ

When is Nuvalent (NUVL) presenting at the 2025 J.P. Morgan Healthcare Conference?

Nuvalent (NUVL) will present at the conference on Tuesday, January 14, 2025, at 9:00 a.m. PT in San Francisco.

How can investors watch Nuvalent's (NUVL) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via live webcast through the Investors section of Nuvalent's website at www.nuvalent.com. The recording will be archived for 30 days after the presentation.

What is the focus of Nuvalent's (NUVL) drug development program?

Nuvalent focuses on creating precisely targeted therapies for clinically proven kinase targets in cancer as a clinical-stage biopharmaceutical company.